Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.

Molecular bioSystems - 1 Apr 2012

Sun Ning, Liang Jing, Abil Zhanar, Zhao Huimin

Abstract excerpt

TAL effector nucleases (TALENs) represent a new class of artificial nucleases capable of cleaving long, specific target DNA sequences in vivo and are powerful tools for genome editing with potential therapeutic applications. Here we report a pair of custom-designed TALENs for targeted genetic correction of the sickle cell disease mutation in human cells, which represents an example of engineered TALENs capable of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to beta-Globins
Share to Endonucleases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Loci

Share to HEK293 Cells

Share to HeLa Cells

Share to Histones

Share to Immunoblotting

Source

Identifiers

PMID: 22301904
DOI: 10.1039/c2mb05461b

Genes

HBB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.PMID 22301904Read ↗

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.Semantic proximity Read ↗

Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Semantic proximity Read ↗

Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.Semantic proximity Read ↗

Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes.Semantic proximity Read ↗

A TALEN genome-editing system for generating human stem cell-based disease models.Semantic proximity Read ↗

Designing and testing the activities of TAL effector nucleases.Semantic proximity Read ↗

Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell diseaseSemantic proximity Read ↗

Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells.Semantic proximity Read ↗

A library of TAL effector nucleases spanning the human genome.Semantic proximity Read ↗

Revolutionising healing: Gene Editing's breakthrough against sickle cell diseaseSemantic proximity Read ↗

Direct delivery of stabilized Cas-embedded base editors achieves efficient and accurate editing of clinically relevant targetsSemantic proximity Read ↗

Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.